HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00192660 |
Recruitment Status :
Completed
First Posted : September 19, 2005
Last Update Posted : April 12, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV-Associated Lipodystrophy Syndrome Cardiovascular Disease | Drug: Lamivudine Drug: Stavudine Drug: Didanosine Drug: Zidovudine Drug: Tenofovir Drug: Abacavir Drug: Efavirenz (EFV) Drug: Nevirapine Drug: Indinavir Drug: Saquinavir Drug: Amprenavir Drug: Ritonavir Drug: Nelfinavir Drug: Tipranavir Drug: enfuvirtide (T20) | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 80 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Structure in HIV-infected Individuals, Naive to Therapy, Who Are Starting Therapy for the First Time |
Study Start Date : | February 2003 |
Actual Primary Completion Date : | October 2006 |
Actual Study Completion Date : | December 2007 |
- To investigate changes in adipocyte structure and function in HIV-infected individuals treated with antiretroviral therapy
- To correlate changes in adipocyte function with changes in body composition and metabolic parameters in individuals beginning their first antiretroviral regimen
- To examine changes in adipocyte function in HIV-infected volunteers both prior to and after initiation of treatment in order to determine changes arising directly as a result of therapy
- To investigate changes in adipocyte function in pre-treated HIV-infected volunteers with and without established signs of HIVLD in order to determine if changes in function correlate with particular phenotypes such as lipoatrophy or buffalo hump

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age >18.
- Be able to provide written consent to perform in the trial.
- HIV antibody positive at time of entry to the study.
Specific to HIV Infection and Metabolic Abnormalities Protocol 1 (HAMA) part A only:
- Be naive to antiretroviral medication.
Specific to HAMA part B only:
- Have had a minimum total exposure to antiretroviral medications (to include drugs from more than one drug class) of 48 weeks at time of recruitment.
- Have had a minimum of 48 weeks interval since completion of HAMA part A.
Exclusion Criteria:
- Any history of, or ongoing, mental or physical condition (including suspected or known diagnosis of ischaemic heart disease), which, in the opinion of the investigator, would impede the subject's ability to participate in the trial.
- Prior use of growth hormone or glucocorticoid or anabolic steroid products within the previous six months.
- Prior use of supraphysiological doses of testosterone or oestrogen replacement therapy within the previous year.
- Alcohol or substance abuse which in the opinion of the investigator would affect the patients ability to participate in the trial.
- Prior use of any retinoid-containing compound within the previous six months.
- Abnormal coagulation.
- Previous allergic reaction or known allergy to local anaesthetic.
- Previous or concomitant use of medications, which, in the opinion of the investigator, would affect the subject's ability to participate in all activities involved in the trial.
- Any grade-three laboratory abnormality recorded from screening bloods, which, in the opinion of the investigator, would impede the subject's ability to safely complete all study requirements.
- Any finding on screening clinical examination, which, in the opinion of the investigator, would impede the subject's ability to participate in the rest of the trial.
- Pregnancy
Specific to HAMA part A only:
- Prior use of anti-retroviral agents (including protease inhibitors, nucleoside or non-nucleoside reverse transcriptase inhibitors, investigational antiretroviral agents or fusion inhibitors). Entry of individuals who have had previous antiretroviral therapy as part of post exposure prophylaxis will be at the discretion of the study investigators.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00192660
Australia, New South Wales | |
St. Vincent's Hospital | |
Sydney, New South Wales, Australia, 2010 |
Principal Investigator: | Andrew D Carr, MD | St. Vincents Hospital Sydney Limited | |
Study Director: | David A Cooper, MD | The National Centre in HIV Epidemiology and Clinical Research, Sydney |
Responsible Party: | Kirby Institute |
ClinicalTrials.gov Identifier: | NCT00192660 |
Other Study ID Numbers: |
HAMA 001 Version 6 R01HL065953-01 ( U.S. NIH Grant/Contract ) |
First Posted: | September 19, 2005 Key Record Dates |
Last Update Posted: | April 12, 2012 |
Last Verified: | April 2012 |
HIV Metabolic abnormality Lipodystrophy Cardiovascular disease |
Treatment Naive Treatment Experienced HIV Infections |
HIV-Associated Lipodystrophy Syndrome Cardiovascular Diseases Lipodystrophy HIV Infections Blood-Borne Infections Communicable Diseases Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Immunologic Deficiency Syndromes Immune System Diseases |
Skin Diseases, Metabolic Skin Diseases Lipid Metabolism Disorders Metabolic Diseases Ritonavir Nelfinavir Indinavir Saquinavir Amprenavir Tenofovir Lamivudine Zidovudine Nevirapine Abacavir Didanosine |